The United States Food and Drug Administration has approved a new leukemia treatment today. It was produced by Teva Pharmaceutical Industries Ltd under the brand name Synribo. The drug is known as omacetaxine mepesuccinate and it treats a very specific form of leukemia. The type of cancer is called chronic myelogenous, which affects the blood and bone marrow. It is known by its acronym CML. It is a common form of leukemia and has a survival rate of 89%.
The treatment of CML is through multiple drugs known as tyrosine kinase inhibitors. This new drug is an option for patients who are unable to take the regular treatment, or do not respond to it. Richard Pazdur, director of the Office of Hematology and Oncology Products from the FDA’s Center for Drug Evaluation and Research issued a statement about the new drug. “Today’s approval provides a new treatment option for patients who are resistant to or cannot tolerate other FDA-approved drugs for chronic or accelerated phases of CML.”
Hopefully with the new drug available, the survival rate for CML will be elevated.